8-K: Simulations Plus Q1 FY26: Services Up, Software Down

Simulations Plus reported a 3% total revenue decrease to $18.4 million for Q1 fiscal 2026, driven by a 17% decline in software revenue, despite a 16% increase in services revenue.

Summary

• Total revenue decreased 3% to $18.4 million for the first quarter fiscal 2026, compared to $18.9 million in Q1 FY25.
• Software revenue decreased 17% to $8.9 million, representing 48% of total revenue, down from $10.7 million in Q1 FY25.
• Services revenue increased 16% to $9.5 million, representing 52% of total revenue, up from $8.2 million in Q1 FY25.
• Gross profit was $10.9 million, with a gross margin of 59%, an increase from $10.2 million and 54% in Q1 FY25.
• Net income for the quarter was $0.7 million, resulting in diluted earnings per share (EPS) of $0.03, compared to net income of $0.2 million and diluted EPS of $0.01 in Q1 FY25.
• Adjusted EBITDA was $3.5 million, representing 19% of total revenue, a decrease from $4.5 million (24% of total revenue) in Q1 FY25.
• Adjusted net income was $2.6 million and adjusted diluted EPS was $0.13, compared to $3.4 million and $0.17, respectively, in Q1 FY25.
• The company reaffirmed its fiscal year 2026 guidance, projecting total revenue between $79 million and $82 million (0-4% growth), software mix of 57-62%, Adjusted EBITDA margin of 26-30%, and Adjusted diluted EPS between $1.03 and $1.10.

Sentiment

Score: 6

Explanation: While total revenue and adjusted EBITDA declined, the company met its guidance, saw strong services growth, and reaffirmed full-year outlook, indicating stability despite some headwinds in software. The focus on AI and upcoming Investor Day also adds a positive future-oriented aspect.

Positives

• Services revenue grew significantly by 16% to $9.5 million, driven by commercialization offerings and development projects.
• Gross profit increased to $10.9 million, and gross margin improved to 59% from 54% year-over-year.
• Net income and diluted EPS increased to $0.7 million and $0.03, respectively, from $0.2 million and $0.01 in the prior year.
• Strong bookings were observed in both the software and services segments.
• Anticipated positive impact from annual software price increases.
• Favorable market dynamics, including most-favored nation pricing agreements and an improved funding environment for clients, are encouraging.
• The company is well-positioned to capitalize on potential upside if client spending levels improve.

Negatives

• Total revenue decreased by 3% to $18.4 million compared to the prior year's first quarter.
• Software revenue declined by 17% to $8.9 million, primarily due to an expected decrease in clinical operations and development revenue.
• Adjusted EBITDA decreased to $3.5 million (19% of total revenue) from $4.5 million (24% of total revenue) in the prior year.
• Adjusted net income and adjusted diluted EPS both decreased year-over-year.
• Software renewal rates were impacted by client consolidations and site closures.

Risks

• Forward-looking statements involve substantial risks and uncertainties, and actual results could differ significantly.
• The effectiveness of the company's internal operational structure could impact performance.
• Ability to maintain competitive advantages and successfully commercialize AI and cloud-enabled solutions.
• Evolving regulatory and data privacy standards governing AI technologies pose a risk.
• Acceptance of new software and improved versions of existing software by customers is not guaranteed.
• The general economics of the pharmaceutical industry can adversely affect business.
• Ability to finance growth and attract and retain highly qualified technical staff are critical factors.
• Market conditions and macroeconomic factors could impact financial results.
• The sustainability of the market for the company's products and services is a factor.

Future Outlook

Simulations Plus reaffirmed its fiscal year 2026 guidance, projecting total revenue between $79 million and $82 million, representing 0-4% growth. The company expects software to comprise 57-62% of revenue, with an Adjusted EBITDA margin of 26-30% and Adjusted diluted EPS between $1.03 and $1.10. Management is confident in achieving this guidance due to strong bookings and annual software price increases, and believes the company is well-positioned to capitalize on improved client spending. The company is also poised to be a leader in model-informed and AI-enabled drug development.

Management Comments

• "We met our first quarter revenue guidance and delivered strong performance in our services segment, driven primarily by significant growth in commercialization offerings and modest gains in development projects."
• "In software, the expected decrease in clinical operations and development revenue was only partially offset by an increase in discovery solutions."
• "We are encouraged by favorable market dynamics, including most-favored nation pricing agreements and an improved funding environment for our clients."
• "With strong bookings in both software and services, along with the impact of annual software price increases, we remain confident in achieving our fiscal year 2026 guidance."
• "Additionally, we believe we are well-positioned to capitalize on any upside should client spending levels improve from current levels."
• "Simulations Plus is poised to be a leader in the next era of model-informed and AI-enabled drug development, and we look forward to sharing our integrated product vision at our virtual Investor Day later this month."

Industry Context

The company notes favorable market dynamics, including most-favored nation pricing agreements and an improved funding environment for its clients in the biopharma sector. This suggests a potentially improving, though still cautious, spending environment within the pharmaceutical industry, which is crucial for a company providing drug development software and services. The focus on AI-enabled drug development aligns with a broader industry trend towards leveraging advanced technologies for efficiency and innovation.

Stakeholder Impact

• Shareholders: Mixed results with revenue decline but reaffirmed guidance; potential for future growth through AI and improved market conditions.
• Employees: Continued focus on attracting and retaining highly qualified technical staff, suggesting stable employment.
• Customers: Benefit from new product vision and AI solutions, and potentially improved funding environment.

Next Steps

• Host an investor conference call on January 8, 2026, at 5:00 p.m. Eastern Time to discuss results and forward-looking information.
• Hold a Virtual Investor Day on Wednesday, January 21, 2026, from 1:00 PM ET-2:30 PM ET, to present new product vision and AI solutions.

Key Dates

Recommendation

The company reported a decline in total revenue and software revenue, which is a concern. However, the strong growth in services revenue and the reaffirmation of full-year guidance suggest that management has a handle on the business and expects to meet its targets. The upcoming Investor Day focused on AI solutions presents a potential catalyst for future growth. Given the mixed results but stable outlook, a 'hold' recommendation is appropriate for investors to observe the execution of the reaffirmed guidance and the impact of new product initiatives.

Keywords

Simulations Plus, SLP, Q1 FY26, Financial Results, Drug Development, AI, Software, Services, Biopharma, Earnings, Pharmaceutical Industry, Model-informed Drug Development, Adjusted EBITDA, EPS, Revenue